BX : Summary for The Blackstone Group L.P. Commo - Yahoo Finance

U.S. Markets closed

The Blackstone Group L.P. (BX)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
30.43+0.15 (+0.50%)
At close: 4:01PM EDT

30.43 0.00 (0.00%)
After hours: 7:59PM EDT

People also watch
KKRMSFIGGSBLK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close30.28
Open31.10
Bid0.00 x
Ask0.00 x
Day's Range30.14 - 31.17
52 Week Range22.45 - 31.69
Volume9,706,394
Avg. Volume4,343,112
Market Cap35.83B
Beta1.25
PE Ratio (TTM)19.47
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.88 (6.43%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire6 hours ago

    Blackstone Mortgage Trust and Walker & Dunlop Announce Multifamily Bridge Lending Exclusive Joint Venture

    NEW YORK, April 24, 2017 /PRNewswire/ -- Blackstone Mortgage Trust, Inc. (BXMT) and Walker & Dunlop, Inc. (WD) today announced that they have entered into a joint venture to originate, hold and finance multifamily bridge loans. Walker & Dunlop, one of the nation's largest nonbank originators of Fannie Mae, Freddie Mac and U.S. Department of Housing and Urban Development loans, will contribute 15% of the venture's equity capital and BXMT will contribute 85%.  The joint venture's floating rate, first mortgage loan product targets assets prior to their eligibility for permanent agency financing.  This comprises an addressable market estimated to be upwards of $20 billion.

  • Backstone Buys Into Permian For $2 Billion
    Oilprice.com2 days ago

    Backstone Buys Into Permian For $2 Billion

    Blackstone is buying into the Permian with an acquisition of EagleClaw Midstream Ventures, LLC and its financial sponson EnCap Flatrock Midstream

  • Cramer's lightning round: This drug stock is simply not good enough for your portfolio
    CNBC3 days ago

    Cramer's lightning round: This drug stock is simply not good enough for your portfolio

    Jim Cramer flies through his take on caller favorite stocks, including this struggling drugmaker.